Author: masuuglobal
What are Good Practice (GxP) Guidelines and Regulations?
What are Good Practice (GxP) Guidelines and Regulations? In the pharmaceutical and life sciences industries, maintaining product quality, safety, and regulatory compliance is essential. Good Practice (GxP) guidelines are a set of quality regulations that ensure drugs, medical devices, and healthcare products are consistently produced, tested, and monitored according to strict standards.
What Is eCTD Submission? A Complete Guide for Pharmaceutical Companies
What Is eCTD Submission? A Complete Guide for Pharmaceutical Companies With the pharmaceutical industry being highly regulated today, the regulatory submissions must be precise, organized, and in line with international standards. The Electronic Common Technical Document (eCTD) is one of the most popular forms of regulatory submissions.
What Is eCTD Software? A Complete Guide for Regulatory Submissions
What Is eCTD Software Regulatory submissions in the pharmaceutical and life sciences industry should be done under stringent world standards. The regulatory bodies in most countries of the world demand that the companies provide huge amounts of paperwork in regard to the development of drugs, clinical trials, and quality of the products.
What is Quality Assurance (QA) in Pharma?
What is Quality Assurance (QA) in Pharma? Quality Assurance (QA) is a critical component of the pharmaceutical industry that ensures medicines are consistently developed, manufactured, and distributed according to established quality standards. Pharmaceutical products must meet strict regulatory and safety requirements before reaching patients.
What is an IND Application (Investigational New Drug Application)
What is an IND Application (Investigational New Drug Application) In the pharmaceutical industry, new drugs must undergo rigorous evaluation before they can be tested in humans. One of the most important regulatory steps in this process is the Investigational New Drug Application (IND). The IND allows pharmaceutical companies to begin clinical trials and ensures that… Continue reading What is an IND Application (Investigational New Drug Application)
How to Respond to FDA Form 483 Observations After a Drug CGMP Inspection
Responding to FDA Form 483 Observations After a Drug CGMP Inspection Regulatory checks are very essential in the aspect of making sure that pharmaceutical producers are adhering to the existing requirements of Good Manufacturing Practice (CGMP). In an inspection, U.S. Food and drug administration (FDA) might find conditions that may be against regulatory provisions. Such… Continue reading How to Respond to FDA Form 483 Observations After a Drug CGMP Inspection
FDA Draft Guidance on Biosimilar Development and the BPCI Act – Key Updates for Pharmaceutical Companies
Understanding the FDA Draft Guidance on Biosimilar Development and the BPCI Act (Revision 4) The U.S. Food and Drug Administration (FDA) released New and Revised Draft Q&As on Biosimilar Development and the BPCI Act (Revision 4) in March 2026 to clarify regulatory expectations for biosimilar and interchangeable biological products.
What is Quality by Design (QbD) in Regulatory Affairs?
What is Quality by Design (QbD) in Regulatory Affairs? Quality by Design (QbD) in Regulatory Affairs is a systematic, science-based approach to pharmaceutical development that focuses on building quality into a product from the earliest stages rather than testing it at the end.
What is a Pre-IND Meeting for US FDA?
What is a Pre-IND Meeting for US FDA? A Pre-IND meeting for the US FDA is a formal meeting between a drug sponsor and the U.S. Food and Drug Administration (FDA) that takes place before submitting an Investigational New Drug (IND) application. The purpose of this meeting is to obtain regulatory guidance on the planned… Continue reading What is a Pre-IND Meeting for US FDA?
What is a Periodic Benefit-Risk Evaluation Report (PBRER)?
What is a Periodic Benefit-Risk Evaluation Report (PBRER)? A Periodic Benefit-Risk Evaluation Report (PBRER) is a comprehensive pharmacovigilance document submitted by Marketing Authorization Holders (MAHs) to regulatory authorities to evaluate a medicine’s ongoing safety profile and its overall benefit-risk balance. The PBRER provides a structured analysis of new safety data collected during a defined reporting… Continue reading What is a Periodic Benefit-Risk Evaluation Report (PBRER)?